Our Company

Aileron Therapeutics (NASDAQ:ALRN) is the clinical-stage leader in the field of stabilized, cell-permeating peptides to treat cancer and other diseases.

About Aileron

Aileron Therapeutics is a clinical stage company discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides.

Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that is currently being evaluated in a Phase 1b/2 clinical trial to protect cancer patients against chemotherapy-induced toxicities, and in a Phase 2 clinical trial in combination with Pfizer’s palbociclib (Ibrance®) for the treatment of patients with MDM2-amplified advanced solid tumors.

Emerging ALRN-6924 clinical results and substantial preclinical data support its use across multiple cancer types as a monotherapy or as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron is exploring collaboration opportunities regarding ALRN-6924 and in other areas where Aileron’s proprietary platform of stabilized cell-permeating peptides can be applied such as targeted protein degradation, and the Bcl-2 family of cancer targets.